Tvardi Therapeutics, Inc. (TVRD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1407553072
Tvardi Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -26.75 m USD |
| EBIT | -18.91 m USD |
| Net income | -18.21 m USD |
| Diluted EPS – continuing operations | -3.26 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
More stocks
- MERCER INTERNATIONAL INC. (MERC)
- Acumen Pharmaceuticals, Inc. (ABOS)
- Citius Pharmaceuticals, Inc. (CTXR)
- FIREFLY NEUROSCIENCE, INC. (AIFF)
- Allarity Therapeutics, Inc. (ALLR)
- TAO Synergies Inc. (TAOX)
- Teads Holding Co. (TEAD)
- Inhibitor Therapeutics, Inc. (INTI)
- NOMAD POWER SOLUTIONS, INC. (NMAD)
- Bionano Genomics, Inc. (BNGO)
- NOBLE ROMANS INC (NROM)
- ACTUATE THERAPEUTICS, INC. (ACTU)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.